Omega 3 supplements
It is optional for a patient with LOS more than 2 weeks as an isolated symptom or following resolution of any other COVID symptoms. The flow chart (Figure 1) summarizes key points in relation to treatment, investigations and management of new onset anosmia during the COVID 19 pandemic.
*Denotes items where consensus was achieved at 60% and not the 70% threshold, highlighting ongoing uncertainty regarding usage. We therefore suggest that decisions regarding usage should be made at an individual patient level, considering the risks in view of comorbidities and individual patient preferences